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Abstract
Purpose: This study aimed to evaluate the prevalence of oral changes and their association 
with graft versus host disease (GVHD) in patients undergoing bone marrow transplantation 
(BMT).
Methods: The sample consisted of 51 BMT patients. A questionnaire was used to collect data 
on age, gender, disease, type and time of transplant, cell origin, and GVHD occurrence. The 
extraoral and intraoral clinical examinations were performed by specialized professionals.
Results: Systemic GVHD was observed in 32.5% of the allogeneic transplant patients, and all of 
the patients with GVHD had oral manifestations. There was a statistically significant association 
between systemic GVHD and oral manifestations (P<0.001).
Conclusion: Given the relatively high prevalence of oral changes associated with GVHD 
in patients undergoing BMT, this study confirms the need to consider dental aspects in the 
examination, diagnosis, treatment and prognosis of possible complications after BMT.
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Resumo
Objetivo: Este estudo objetivou avaliar a prevalência de alterações orais e sua associação 
com a doença enxerto versus hospedeiro (DEVH) em pacientes submetidos a transplante de 
medula óssea (TMO).
Metodologia: A amostra consistiu de 51 pacientes. Por meio de questionário, foram 
coletados dados sobre idade, sexo, doença, tipo e tempo de transplante, origem das células 
e ocorrência da DEVH. Foram realizados exames clínicos extra e intraoral por profissionais 
especializados.
Resultados: DEVH sistêmica foi observada em 32,5% dos pacientes transplantados alogênicos, 
todos apresentando manifestações orais. Também houve uma associação estatisticamente 
significante entre DEVH sistêmica e manifestações orais (P<0,001).
Conclusão: Diante da prevalência de alterações orais relativamente alta associada à DEVH 
em pacientes submetidos ao TMO, o presente estudo confirma a necessidade de se considerar 
a odontologia no exame, diagnóstico, tratamento e prognóstico de possíveis complicações 
após o transplante de medula óssea.
Palavras-chave: Transplante de medula óssea; doença enxerto-hospedeiro; manifestações 
orais
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Introduction
Bone marrow transplantation (BMT) is the therapeutic 
modality used in the treatment of many benign or malignant, 
inherited or acquired hematologic diseases (1,2). BMT is 
characterized by the removal of stem cells from the donor, 
which may be the patient himself (autologous transplant) or 
another compatible donor (allogeneic transplant), and the 
infusion of these cells into the patient after a conditioning 
period (2-4). Progenitor cells infused into the bloodstream 
are implanted in the bone marrow, promoting hematopoietic 
reconstitution (4,5).
The annual frequency of performing BMT with high 
success rates are growing exponentially due to a greater 
knowledge of the human histocompatibility system and 
accurate examinations in the selection of bone marrow 
donors. However, graft versus host disease (GVHD) still 
represents one of the most common complications after 
allogeneic transplant (3).
GVHD is a complication that occurs through the 
activation of T cells in response to molecules from the 
major histocompatibility complex (MHC) after an allogeneic 
histocompatible BMT. Donated T cells recognize molecules 
from the host tissue as foreign (3-5). The incidence of GVHD 
varies from 6 to 80% according to patient age, donor type, 
stem cell source, graft manipulation and use of lymphocyte 
infusions after the transplant (6).
The clinical manifestations of GVHD can affect the skin, 
liver, gastrointestinal tract and/or lymphoid system (3,4) and 
may present an acute or chronic form (5). Oral lesions may 
be associated with GVHD and are present in 25 to 70% of the 
cases (6-8). They are characterized by erythematous areas, 
ulcers and/or pain, and the most commonly involved regions 
are the buccal mucosa and tongue (9). In addition, some 
studies have shown that the oral mucosa of BMT recipients 
represents a favorable environment for the development 
of various manifestations, such as mucositis, lichenoid 
reaction, fungal and herpetic infections, hairy leukoplakia, 
pigmentation, thrombocytopenic purpura, and spontaneous 
gingival alterations independent of dental biofilm and 
malignant neoplasms (2,10,11). Thus, this association 
emphasizes the importance of dentistry in the diagnosis and 
clinical management of these patients.
Taking into account the increasing inclusion of BMT 
as an indication for the treatment of malignant and non-
malignant hematologic diseases and the frequent occurrence 
of GVHD with manifestations in the oral cavity, this study 
aims to evaluate the prevalence of oral abnormalities in these 
patients and verify their association with GVHD in cases of 
allogeneic BMT.
Methodology
The project was approved by the “Research Ethics 
Committee of the Federal University of Rio Grande do 
Norte” in accordance with national and international 
guidelines and regulations.
Study design and sample
This study is characterized as a prevalence study with a 
cross-sectional design. The population was represented by 
all bone marrow transplanted patients registered from 2004 
to 2011 at a referral center for BMT in Natal, Rio Grande do 
Norte state, Brazil. There were 63 patients registered during 
the selected period. We included those who showed good 
physical and psychological states so that they could answer 
a questionnaire and undergo a clinical examination of the 
oral cavity upon authorization by the attending physician. 
The study excluded individuals who showed unfavorable 
physical and/or psychological conditions. Thus, the final 
sample consisted of 51 patients who sought dental treatment 
at the Clinic of Oral Diagnosis in the Dentistry Department 
of the Federal University of Rio Grande do Norte.
Data collection
A questionnaire was used to collect data on age, gender and 
disease, as well as information related to the transplant (type, 
time of transplantation, and source of the transplanted cells) 
and complications during treatment, such as the occurrence 
of systemic GVHD, which were previously diagnosed by the 
medical team as functional complications of the skin, liver, 
gastrointestinal tract or lymphoid system. 
Patients underwent an extra- and intraoral clinical 
examination to identify possible injuries. The evaluation 
was conducted by two professionals, who were previously 
trained to identify the following conditions: mucositis, 
lichenoid reaction, thrombocytopenic purpura, pigmentation, 
candidiasis, and gingival changes unrelated to dental biofilm. 
Symptoms such as reduced salivary flow and xerostomia 
were excluded from analysis because they are already well 
recognized features in the literature. 
The statistical data analysis was performed using the 
SPSS program (Statistical Package for the Social Sciences), 
version 17.0. Categorical variables are presented as absolute 
and relative frequencies and were subjected to analysis 
by chi-square tests. To analyze the frequency of oral 
abnormalities at different times after BMT, the continuous 
variable “time” was categorized as “≤ 100 days” and “> 100 
days”. Thus, we could analyze the most frequent period of 
oral manifestations. A significance level of 5% (α = 0.05) 
was set for all tests.
Results
There was no significant predominance for gender, with 
a slight tendency towards females (27/51; 53%) over males 
(24/51; 47%). Patient age ranged from 5 to 54 years old, with an 
average of 34.6 years old. There was a predominance of acute 
myeloid leukemia (24/51; 47%), followed by chronic myeloid 
leukemia (8/51; 16%) and multiple myeloma (6/51; 12%).
With regard to the transplants performed, there was a 
predominance of the allogeneic type (40/51; 78%). The 
time of the transplant ranged from 0 to 1,291 days, with an 
average of 370.4 days.
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Graft versus host disease (GVHD) was observed in 
32.5% (13/40) of the patients undergoing allogeneic 
BMT (Table 1), and approximately half of all patients 
presented oral manifestations (25/51; 49%). Some patients 
had more than one type of lesion in the oral cavity. The 
observed manifestations are listed in Table 2 and shown 
in Fig. 1.
Oral Manifestation
Time
≤ 100 days > 100 days Total
n % n % n %
Mucositis 5 9.8 9 17.6 14 27.5
Spontaneous gingival changes 3 5.9 3 5.9 6 11.8
Thrombocytopenic purpura 5 9.8 1 2 6 11.8
Pigmentation 0 0 4 7.8 4 7.8
Lichenoid reaction 0 0 2 3.9 2 3.9
Candidiasis 1 2 1 2 2 3.9
Table 1. Distribution of cases according to sex and the presence 
of GVHD in patients undergoing allogeneic bone marrow 
transplantation in the ION/Natal Hospital Center, Brazil, 
Natal-RN, 2011.
GVHD
Gender
Total
Male Female
n % n % n %
Not 10 25 17 42.5 27 67.5
Yes 8 20 5 12.5 13 32.5
Total 18 45 22 55 40 100.0
Table 2. Distribution of oral abnormalities 
in patients undergoing allogeneic BMT 
according to the time of transplantation 
at the ION/Natal Hospital Center, 
Brazil, Natal-RN, 2011.
Fig. 1. Oral manifestations of 
BMT patients. (A) Mucositis 
in the tongue, with evident 
areas of erythema and 
ulcerations. (B) Gingival 
change characterized by the 
presence of inflammation 
and an erythematous area; 
note the absence of dental 
biofilm.(C) Thrombocytopenic 
purpura represented by red 
and purple pigmentation on 
the mouth floor. (D) Brownish 
pigmentation on the lower lip. 
(E) Lichenoid reaction in the 
buccal mucosa. (F) Atrophic 
candidiasis as represented by 
a red area with white edges on 
the dorsum of the tongue.
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In all cases of allogeneic transplants with GVHD, 
we observed oral manifestations. There was a significant 
association between the presence of changes in the oral 
cavity and GVHD in the allogeneic transplants (P < 0.001) 
(Table 3). The results regarding the type of transplant 
performed and the origin of the transplanted cells are shown 
in Table 4. There was no statistically significant association 
between these variables.
Discussion
After BMT, some patients develop changes in the oral 
cavity, often in association with GVHD (12). Risk factors, 
such as prolonged hospitalization, changes in the oral 
microbiota, the use of broad-spectrum antibiotics, pre-
existing dental infections, poor oral hygiene and nutritional 
status, may contribute to the increased incidence and severity 
of oral complications in BMT patients (13). Because the oral 
cavity has a large number of microorganisms, it can serve 
as a source of infection during severe myelosuppression, 
aggravating the clinical condition of the patients (1).
In the present investigation, the most frequent diseases 
presented by the patients were acute myeloid leukemia, 
chronic myeloid leukemia, and multiple myeloma, in 
agreement with the literature with regard to the major 
diseases with an indication for BMT (2). The most common 
type of transplant was allogeneic, with a similar use of cells 
from the peripheral blood and bone marrow. This profile of 
the patients with an indication for BMT is consistent with 
that in the literature (14). The low number of autologous 
transplants was expected because this type of transplantation 
is still being implemented in the center where the study was 
performed, while the allogeneic transplantations are more 
frequent. This bias is a limitation of the present study and 
might have impacted some aspects of the results.
In the present study, graft versus host disease (GVHD) 
was observed in 32.5% of patients, with most cases presenting 
the chronic form without an association with the origin of 
the transplanted cells. The dental literature also reports an 
incidence of 30 to 70% for this disease  after allogeneic 
BMT, with a predominance of the chronic form (2,4,5). 
Oral changes were found in 49% of all patients, sometimes 
as part of GVHD, which is similar to a previous report (15). 
The graft versus host disease was assessed only in relation to 
gender because the study group did not show large variations 
in the other variables.
Despite affecting a small percentage of patients, oral 
mucositis represents the most frequent manifestation in the 
study. Such damage is reported as being the most prevalent 
adverse effect in cancer patients under various treatment 
modalities (16), including BMT (14,17,18). Therefore, in such 
cases, mucositis can be recognized as toxicity related to the 
conditioning regimen (19). However, in patients with GVHD, 
this manifestation characterizes the pathophysiology of the 
disease and is not related to the conditioning treatment (15).
Pereira Pinto et al. (18) evaluated the clinical aspects 
of the oral mucosa in children with acute lymphoblastic 
leukemia after prophylactic mouthwash with chlorhexidine 
0.12%. They observed a significant decrease in the incidence 
of oral mucositis and ulcerations, suggesting the systematic 
use of a preventive protocol for these patients. Another 
treatment option is phototherapy, which has shown good 
results for reducing pain after BMT (16).
The lichenoid reaction and fungal infection were less 
frequent oral changes. Although the lichenoid reaction is 
considered one of the main diagnostic features of GVHD 
and is widely observed in BMT patients (6), this change 
occurred in only two patients in this sample, both of whom 
presented clinical signs of GVHD. Fungal infections were 
previously reported in 15 to 56% of patients undergoing 
GVHD
Oral Manifestations
Total
n (%) χ
2 PAbsent
n (%)
Present
n (%)
Absent 26 (68.4) 12 (31.6) 38 (100.0) 18.145 < 0.001*
Present 0 (0.0)   13 (100.0) 13 (100.0)
* Chi-square test.
Parameters
Oral manifestations
χ2 PAbsent
n (%)
Present
n (%)
Type of transplant 2.654 0.103*
Allogeneic 18 (69.2) 22 (88.0)
Autologous 8 (30.8) 3 (12.0)
Total: n(%) 26 (100.0) 25 (100.0)
Cell origin
Bone marrow 11 (42.3) 21 (52.0) 0.481 0.488*
Peripheral blood 15 (57.7) 19 (48.0)
Total: n(%) 26 (100.0) 25 (100.0)
* Chi-square test.
Table 4. Distribution of oral manifestations 
according to the type of transplant and origin 
of the cells at the ION/Natal Hospital Center, 
Brazil, Natal-RN, 2011.
Table 3. Distribution of oral manifestations 
according to the occurrence of GVHD at the 
ION/Natal Hospital Center, Brazil, Natal-
RN, 2011.
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BMT (20), but the early diagnosis of oral candidiasis is often 
hindered by the presence of other injuries, such as mucositis. 
Thus, systemic prophylaxis is still recommended in states 
of immunosuppression. In the BMT Center where this study 
was conducted, the clinical protocol includes prophylactic 
antifungal medications, which was most likely reflected in 
the low occurrence of candidiasis (4%).
Regarding the type of transplant performed, the highest 
incidence of oral abnormalities is reported in cases of 
allogeneic BMT, often related to DECH (4,21). Confirming 
these findings, the majority of oral lesions in this investigation 
occurred in cases of allogeneic transplants (88%). However, 
there was no statistically significant association between 
oral abnormalities and the type of transplant performed. The 
period of development for oral abnormalities can range from 
the first day after BMT up to long post-transplant periods of 
time (13). However, late manifestations are more frequent, 
especially when associated with the presence of DECH (22). 
In the studied sample, a higher prevalence of oral lesions was 
found after the 100th day of transplantation, which suggests a 
tendency to chronic or late manifestations in the oral cavity (4).
With respect to the origin of the transplanted cells, 52% 
of the oral abnormalities affected patients transplanted with 
bone marrow cells, and 48% were in patients undergoing 
transplantation with peripheral cells. Similarly to the type of 
transplant, no significant association was found between oral 
abnormalities and the origin of the transplanted cells. In a 
randomized study that compared BMT with cells from the bone 
marrow and from peripheral blood (23), oral abnormalities 
were the most common manifestations of chronic GVHD in 
BMT with bone marrow cells and the second most common 
(after skin) in BMT with peripheral cells, demonstrating a 
high prevalence of oral manifestations.
When analyzing a possible association between oral 
abnormalities and presence of GVHD, we observed that all 
GVHD patients had oral manifestations. This result confirms 
that oral GVHD may be considered a potential risk factor for 
the development of different injuries in the mouth following 
allogeneic BMT (24,25). A significant association between 
oral changes and GVHD shows the importance of adopting 
a protocol for the prevention and long-term monitoring of 
patients, with a focus on improving the oral health status 
and controlling the bacterial flora. A periodic evaluation of 
the oral cavity is recommended to prevent the occurrence 
of severe oral changes, allow the early diagnosis of possible 
systemic complications and GVHD, ensure prompt treatment 
and reduce the burden of these diseases.
Conclusions
The present results show a relatively high frequency 
of oral abnormalities in patients undergoing BMT, most 
commonly represented by mucositis, gingival changes 
unrelated to dental biofilm, and thrombocytopenic purpura. 
These manifestations were more common in allogeneic 
transplantations, with a slight tendency towards a late 
manifestation (more than 100 days post-transplant), which 
is the same period seen in most episodes of GVHD. The late 
onset observed for both GVHD and oral manifestations can 
be explained by the high efficacy of the treatment protocol 
adopted, thereby preventing the lesions during the acute 
phase. A significant association between GVHD and the 
presence of changes in the oral cavity shows the need to 
consider this site a key organ for the examination, diagnosis, 
treatment and prognosis of possible complications of bone 
marrow transplantation.
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